Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients with Coronavirus Disease 2019

Evan M. Bloch*, Daniele Focosi, Shmuel Shoham, Jonathon Senefeld, Aaron A.R. Tobian, Lindsey R. Baden, Pierre Tiberghien, David J. Sullivan, Claudia Cohn, Veronica Dioverti, Jeffrey P. Henderson, Cynthia So-Osman, Justin E. Juskewitch, Raymund R. Razonable, Massimo Franchini, Ruchika Goel, Brenda J. Grossman, Arturo Casadevall, Michael J. Joyner, Robin K. AveryLiise Anne Pirofski, Kelly A. Gebo

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

34 Citations (Scopus)
38 Downloads (Pure)

Abstract

Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is a safe and effective treatment for COVID-19 in immunocompromised (IC) patients. IC patients have a higher risk of persistent infection, severe disease, and death from COVID-19. Despite the continued clinical use of CCP to treat IC patients, the optimal dose, frequency/schedule, and duration of CCP treatment has yet to be determined, and related best practices guidelines are lacking. A group of individuals with expertise spanning infectious diseases, virology and transfusion medicine was assembled to render an expert opinion statement pertaining to the use of CCP for IC patients. For optimal effect, CCP should be recently and locally collected to match circulating variant. CCP should be considered for the treatment of IC patients with acute and protracted COVID-19; dosage depends on clinical setting (acute vs protracted COVID-19). CCP containing high-Titer severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, retains activity against circulating SARS-CoV-2 variants, which have otherwise rendered monoclonal antibodies ineffective.

Original languageEnglish
Pages (from-to)2018-2024
Number of pages7
JournalClinical Infectious Diseases
Volume76
Issue number11
DOIs
Publication statusPublished - 1 Jun 2023

Bibliographical note

Funding Information:
Financial support. E. M. B.'s effort is supported in part by the National Heart Lung and Blood Institute (grant number 1K23HL151826). K. G. reports support for this work made to institution from Octapharma, US Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense, National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (grant number 3R01AI152078-01S1), NIH National Center for Advancing Translational Sciences (grant numbers U24TR001609-S3 and UL1TR00309), Mental Wellness Foundation, HealthNetwork Foundation, Bloomberg Philanthropies, Moriah Fund, Shear family foundation, State of Maryland, Defense Health Agency (grant number W911QY2090012). J. P. H. reports unrestricted gift to Washington University to administer to Henderson laboratory to support activities related to COVID-19 convalescent plasma from Octapharma of Paramus, New Jersey, USA.

Publisher Copyright:
© 2023 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Fingerprint

Dive into the research topics of 'Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients with Coronavirus Disease 2019'. Together they form a unique fingerprint.

Cite this